```html

Vancomycin‑Resistant Enterococcus (VRE) Infection – A Patient‑Friendly Guide

Overview

Vancomycin‑Resistant Enterococcus (VRE) refers to infections caused by strains of the bacteria Enterococcus faecium or Enterococcus faecalis that are no longer killed by the antibiotic vancomycin. Enterococci are normal inhabitants of the gastrointestinal tract, but when they acquire resistance, they can cause serious infections, especially in hospitals and long‑term care facilities.

• Who it affects: Adults over 65, patients with weakened immune systems, those who have undergone recent surgery, and anyone with prolonged exposure to health‑care settings.
• Prevalence: In the United States, the CDC estimated ~54,000 VRE infections and >1,300 deaths annually (2020 data). Europe reports a similar trend, with ECDC citing 19 % of Enterococcus isolates resistant to vancomycin in 2022.
• Transmission: Primarily via direct contact with contaminated hands, surfaces, or medical equipment.

Symptoms

VRE can infect many body sites. The symptom profile depends on the infection’s location.

Urinary Tract Infection (UTI)

• Burning sensation during urination
• Frequent urge to urinate, often with little output
• Cloudy, strong‑smelling, or bloody urine
• Lower abdominal or back pain
• Fever and chills (if infection spreads to kidneys)

Bloodstream Infection (Bacteremia/Sepsis)

• High fever, chills, rapid heartbeat
• Low blood pressure, confusion, or altered mental status
• Generalized weakness and malaise
• Red or purplish patches on the skin (sign of septic emboli)

Wound or Surgical Site Infection

• Redness, warmth, swelling, or pain around the incision
• Pus or foul‑smelling drainage
• Fever, especially >38 °C (100.4 °F)

Endocarditis (Heart‑Valve Infection)

• Persistent low‑grade fever
• Night sweats, weight loss, fatigue
• Shortness of breath or new heart murmur
• Embolic phenomena such as stroke‑like symptoms

Other Possible Presentations

• Peritonitis (abdominal pain, bloating, tenderness) in patients on peritoneal dialysis
• Respiratory infection (cough, sputum, fever) though rare

Causes and Risk Factors

How VRE Develops

Enterococci acquire resistance through genetic mutations or by picking up mobile DNA elements (plasmids) that carry the vanA or vanB genes. These genes alter the bacterial cell wall, preventing vancomycin from binding effectively.

Key Risk Factors

• Recent or prolonged hospitalization: especially intensive care units (ICU) where antibiotics are heavily used.
• Broad‑spectrum antibiotic use: drugs such as cephalosporins, carbapenems, or prolonged vancomycin therapy.
• Invasive devices: urinary catheters, central venous lines, endotracheal tubes, or feeding tubes.
• Immunosuppression: chemotherapy, transplant medications, HIV/AIDS, or corticosteroid therapy.
• Underlying chronic conditions: diabetes, chronic kidney disease, or chronic lung disease.
• Advanced age: immune function declines with age, increasing susceptibility.
• Living in long‑term care facilities: close quarters and frequent antibiotic exposure raise colonization rates.

Diagnosis

Timely identification is crucial because VRE does not respond to standard vancomycin therapy.

Microbiological Tests

• Culture and sensitivity: Samples (urine, blood, wound swab, or stool) are grown on selective media. Laboratory tests determine if the isolate is resistant to vancomycin (MIC ≥ 32 µg/mL).
• Polymerase chain reaction (PCR): Detects vanA or vanB genes directly from clinical specimens, providing results in hours.

Imaging (when indicated)

• Ultrasound or CT for suspected urinary or intra‑abdominal infection.
• Echocardiography (transthoracic or trans‑esophageal) for endocarditis.

Additional Laboratory Work‑up

• Complete blood count (CBC) – often shows elevated white blood cells.
• Serum creatinine and electrolytes – important for dosing nephrotoxic drugs.
• Inflammatory markers (CRP, procalcitonin) – help gauge severity.

Treatment Options

Because VRE is resistant to vancomycin, clinicians rely on alternative agents and a multifaceted approach.

First‑Line Antimicrobial Therapies

• Linezolid: Oral or IV; effective for most VRE strains. Monitor for thrombocytopenia with prolonged use.
• Daptomycin: IV; dosage often ≥ 10 mg/kg for bloodstream infections. Not useful for pneumonia due to surfactant inactivation.
• Tigecycline: IV; considered for complicated intra‑abdominal infections. Caution: higher mortality signal in some studies.
• Quinupristin/dalfopristin (Synercid): IV; active mainly against E. faecium, not E. faecalis.

Combination Therapy

Severe infections (e.g., endocarditis, bacteremia) may require two agents (e.g., daptomycin + linezolid) to achieve synergistic killing and prevent resistance.

Adjunctive Measures

• Source control: Remove or replace contaminated catheters, drainage of abscesses, debridement of infected wounds.
• Supportive care: IV fluids, fever control, oxygen as needed.
• Therapeutic drug monitoring: Especially for linezolid (plasma levels) and daptomycin (CK levels for muscle toxicity).

Lifestyle & Home Care

• Maintain adequate hydration to support kidney function.
• Complete the entire prescribed antibiotic course—even if symptoms improve.
• Follow strict hand‑hygiene and wound‑care instructions given by your provider.

Living with Vancomycin‑Resistant Enterococcus (VRE) Infection

Daily Management Tips

• Hand hygiene: Wash hands with soap and water for at least 20 seconds or use an alcohol‑based sanitizer (≥ 60 % ethanol) before and after touching any medical device.
• Catheter care: Keep urinary and central lines clean, dressings dry, and report any redness or discharge promptly.
• Medication adherence: Use a pill organizer or set alarms; keep a medication list handy for all health‑care encounters.
• Nutrition: Eat a balanced diet rich in protein, fruits, and vegetables to support immune function.
• Follow‑up appointments: Attend all lab draws and clinic visits to monitor drug levels and organ function.
• Alert contacts: Inform close family members and caregivers about VRE status so they can practice proper infection control.

Psychosocial Considerations

Living with a multidrug‑resistant infection can be stressful. Consider joining a support group, speaking with a mental‑health professional, or using hospital‑provided counseling services.

Prevention

• Hand hygiene for health‑care workers: The single most effective measure (CDC Hand Hygiene Guidelines).
• Contact precautions: Gown and gloves when entering rooms of patients known or suspected to have VRE.
• Antibiotic stewardship: Use antibiotics only when necessary and choose narrow‑spectrum agents whenever possible.
• Environmental cleaning: Daily disinfection of high‑touch surfaces with agents effective against VRE (e.g., chlorine‑based or quaternary ammonium compounds).
• Screening: Some hospitals perform rectal swab screening on high‑risk patients (ICU admissions, transplantation) to identify carriers early.
• Vaccination: Keep flu and pneumococcal vaccines up‑to‑date to reduce secondary infections that could require antibiotics.

Complications

If VRE infection is not promptly and adequately treated, serious complications can arise:

• Septic shock: Life‑threatening drop in blood pressure and organ failure.
• Endocarditis: Can lead to heart‑valve destruction, embolic stroke, or heart failure.
• Renal failure: Particularly in patients with pre‑existing kidney disease or when nephrotoxic antibiotics are used.
• Chronic wound infection: May require repeated debridement or even amputation.
• Persistent bacteremia: Increases mortality; up to 30 % 30‑day mortality reported in VRE bloodstream infections.
• Transmission to close contacts: Colonization can spread to family members or other patients, leading to outbreaks.

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. Vancomycin-Resistant Enterococci (VRE). Updated 2023.
2. World Health Organization. Antimicrobial resistance. 2022.
3. Mayo Clinic. VRE infection. Reviewed 2024.
4. Falagas ME, et al. “Treatment of infections caused by vancomycin‑resistant Enterococcus spp.” Clin Microbiol Rev. 2021;34(4):e00225‑20.
5. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2022.
6. Cleveland Clinic. VRE Infection. Accessed April 2026.
7. Infection Control Guidelines, Society for Healthcare Epidemiology of America (SHEA). 2022.

```